Abstract No curative treatment exists for patients with myelodysplastic syndrome (MDS) besides allogeneic stem cell transplantation. Hence, palliative treatment is provided for a life time accruing high health care cost. As no study in cost of MDS exists in Germany, the objective of this study was to assess and analyze costs of transfusion-dependent low/intermediate-1-risk MDS in Germany from a payers' perspective. From seven centers, 116 low/intermediate-1-risk transfusion-dependent MDS patients with and without isolated 5q-deletion were identified. Claims data and patient records of the previous 5 years were used to collect health care utilization data retrospectively. Publicly available tariff books and remuneration schemes were applied to evaluate mean costs per year in Euro with 2007 as base year. The annual cost of MDS patients was estimated at €14,883. Subgroup analyses showed differences in patient's characteristics and outcomes among patients treated at a hospitalbased vs. an office-based setting. Patients treated at the hospital-based registry show higher cost, whereas the reasons for that still need to be detected. Overall, per annum direct costs range from €12,543 (SD 12,967) to €24,957 (SD 36,399) in different subgroups of patients. In both groups, patients with 5q-deletion use more medication than those without deletion. Mean costs for medication in the office-based setting are €5,902 for patients with isolated 5q-deletion vs. €3,932 for patients with no deletion, respectively. MDS leads to a high health care utilization and resulting costs for the health care system which requires a detailed analysis of underlying services.
Introduction
Myelodysplastic syndromes (MDSs) are severe and lifethreatening diseases of the bone marrow resulting in disorderly and ineffective hematopoiesis manifested by irreversible quantitative and qualitative defects in hematopoietic cells. Furthermore, in these patients, the risk of acute myeloid leukemia (AML) is increased. MDS occurs primarily in the elderly with an average age among incident patients of about 60-70 years. Annual incidence in the general population is approximately three to five cases per 100,000, while among individuals of 70 years and older, the incidence is estimated to be fivefold higher with approximately 25 cases per 100,000 [1] . Beyond 50 years of age, the incidence rate among men is about twice as high as in women [2] . Several classifications of MDS exist, two of which are frequently used. The World Health Organization classification is being used as a diagnostic tool based on morphologic factors and cytogenetic findings [3] [4] [5] , and the international prognostic scoring system (IPSS) serves as a prognostic tool.
Interstitial 5q-deletions are the most frequent chromosomal abnormalities in MDS, present in 10% to 15% of MDS patients [6] [7] [8] . The prognosis is favorable with relatively low risk of transformation to AML [9, 10] but the dependence on red blood cell (RBC) transfusions often has a negative effect on morbidity and mortality [10] .
Hematopoietic stem cell transplantation is the only curative therapy for MDS. However, this therapy is primarily applied to individuals who are 60 years and younger. Hence, for many MDS patients, the therapy limits itself to a restricted number of treatments. Most MDS patients develop anemia, which is treated with blood transfusions. Transfusion dependency leads to decreased quality of life [11] as well as life expectancy [12, 13] and produces enormous cost to patients and the health care system [14, 15] . Furthermore, transfusion-dependent patients with a good long-term prognosis require iron chelation therapy for prophylaxis against secondary hemosiderosis [16] [17] [18] . Although erythropoiesis-stimulating agents (ESA) are not FDA-approved for MDS, they are commonly used off label in this disease. In up to 40% of patients, erythropoietin has shown to result in a significant hemoglobin increase or an erythrocyte concentrates (ec) transfusion independency, although its superiority over supportive care is controversially debated. Several studies have been conducted to compare ESA to the best supportive care. The studies are designed differently and yield conflicting results [19] [20] [21] [22] [23] [24] [25] . Recently, lenalidomide was approved for use in the US market. It is a thalidomide analog with a distinct clinical profile that has demonstrated to be very efficacious in 5q-deletion patient subgroups leading to independence from RBC transfusion [26] [27] [28] [29] .
Even more recently, during the annual meeting of the American Society of Hematology (ASH) in 2007, P. Fenaux et al. reported the results of an international, multicenter, prospective, randomized, controlled, parallelgroup, phase III clinical trial comparing azacitidine to conventional care regimen. The results of this study have shown that azacitidine is associated with a statistically and clinically meaningful survival benefit of 9.4 months compared with conventional care in patients with higher-risk MDS (IPSS risk category intermediate-2 or high) [30, 31] .
The average remaining life expectancy of MDS patients after diagnosis varies between 1 to 10 years. Since no curative treatment exists besides hematopoietic stem cell transplantation, all treatments need to be carried out throughout the entire remaining lifetime and lead to considerable economic burden. Until today, only few cost studies of MDS exist and are limited to USA, France, The Netherlands, and Sweden [14, 15, [32] [33] [34] [35] .
Hence, the aim of this study is to estimate the economic burden of transfusion-dependent MDS patients with low or intermediary risk 1 in Germany from a payer's perspective.
Patients and methods
For this cost study, a prevalence-based approach was chosen. This requires less data or assumptions about the course of disease than in an incidence-based costing approach. Furthermore, a prevalence costing approach provides a good picture of the general cost of disease for conditions with a steady incidence, progression, mortality, and treatment [36] . For this study, illness and cost data of patients were collected from seven specialized treatment sites in Germany. Among those were six outpatient specialists' practices and one specialized university-based clinic. Charges for medical services were retrospectively gathered on a quarterly basis over a time frame of up to 5 years for [2001] [2002] [2003] [2004] [2005] [2006] . These resource use data were valued in Euro (base year 2007) using public remuneration schemes to estimate the direct medical costs from a payer's perspective.
Data collection
Inclusion criteria for this study were diagnosis of MDS which was classified as transfusion-dependent low/ intermediate-1-risk MDS. Patients were recruited from the outpatient sector as well as from a hospital-based MDS registry. The recruitment and data collection in the ambulatory sector were carried out by the IORC GmbH in Hamburg, which specialized in the field of data collection in the ambulatory treatment sector in Germany. The patients were recruited from seven outpatient centers. Per center, a maximum of 50 patients were enrolled. To avoid selection bias, the patients were selected at random whenever a center had data on more than 50 patients. The patient's data were collected using an online-based questionnaire that had to be filled out by the respective physician using his/her patient records. For outpatient and inpatient services, EBM points (general statutory health insurance fee scheme for German officebased physicians) and, when available, DRG codes were collected from the claims data, respectively. Drug prescriptions and additional services were also gathered.
From the MDS registry, 16 patients with isolated 5q-deletion were recruited. Because the claims data were not always fully available, recorded services were re-coded according to services as given in the EBM and DRG, afterwards. Beside cost-relevant data, medical disease specific data were collected. This included information about the anamnesis, MDS diagnosis, MDS specific lab values, impairment status, co-morbidities, and insurance status, as well as general demographic data.
Data management and data analysis
The data were checked for duplicates and clarity. Overall, no information on provided services was identified in 37 quarters. As it seems very unlikely for transfusiondependent patients to not receive any care for 3 months, one could assume that information on these quarters was missing not because no services were provided but rather because those services were provided at other institutions. However, as no information on the amount and type of services was available, we neglected the entire quarters in the base case analysis. In a sensitivity analysis, these 37 quarters were included with a value of zero assuming that the information was missing because actually no services were provided. For ambulatory services, EBM points were applied according to the most current remuneration scheme (Kassenärztliche Bundesvereinigung, Einheitlicher Bewertungsmaßstab (EBM) 2000 plus (2007)). Despite possible budgeted or restricted compensation, the EBM points were valued with €0.05 per point. To test the robustness of the study results, a sensitivity analysis was conducted. In this analysis, the point value was varied from €0.03 to €0.055. For inpatient services, cost weights according to the German DRG system (G-DRG Report Browser version 2005/2007) were applied. These values were multiplied with the base case remuneration rate of €2,835 and varied by 10% in sensitivity analyses. Drugs were priced according to the 'Rote Liste' (http://www.roste-liste.de). The costs for transfusions were estimated to be €161.45 and €681.24 per erythrocyte unit and thrombocyte unit, respectively. Since information on transfusion cost varied widely, we tested this assumption also in sensitivity analyses by applying the lowest cost information available of €80 and €350 per erythrocyte unit and thrombocyte unit, respectively.
The data were analyzed with the software SPSS Version 11 (SPSS Version 11.0 (2001), SPSS Inc.,). Cost categories were defined for which the mean and the standard deviation were determined. Further, a subgroup analysis for patients with isolated 5q-deletion was carried out. Statistical tests were used to determine the significance of divergence of both groups. Outliers were determined and excluded.
Results

Patients
A total of 116 patients enrolled by seven centers were analyzed. The patient number per center varied substantially from two patients with a total of eight yearly quarters to 47 patients with a total of 352 quarters. Six centers were ambulatory specialists' offices, while one center (number 7) was a hospital-based ambulatory care unit, specialized for MDS treatment. Most patients with an isolated 5q-deletion in this study were treated in that institution. The characteristics of these patients diverge significantly from patients without a 5q-deletion.
In the examined dataset of patients treated in an officebased setting, the patients without (known) 5q-deletion show to have a greater proportion of males than those with a 5q-deletion (47% male without 5q-deletion, 21% among the patients with 5q-deletion). Furthermore, 5q-patients tend to be younger. (Table 1) Costs The average annual costs for MDS are estimated at €14,883. These costs diverge significantly between settings, i.e., office and hospital setting (€13,455 vs. €24,957, respectively).
Variations between the treatment centers
As shown in Fig. 1 , the average costs according to the cost categories of interest were analyzed for each center independently. The bars represent the centers as titled at the x-axis, while the number of contributed yearly quarters with data per center is shown in the parentheses. Centers 3 and 4 provided data for only eighteen (eight) quarters of three (two) patients, respectively. Statistically, these centers are therefore not relevant for these center-specific analyses and omitted from the graph. The figure shows the existence of a natural variability between the centers. However, center 7 diverges significantly with regard to costs for MDS relevant medication. This is also the case when looking at isolated 5q-deletion separately. For statistical relevance, 5q-patients were categorized into two groups only.
Office-based cost for MDS
To avoid biases, only office-based patient data were included when comparing patients with and without 5q-deletion (Table 2) . Both groups don't show significantly different cost except for inpatient services. Patients with 5q-deletion show to accrue only one third of inpatient services cost. Patients with 5q-deletion tend to accumulate higher cost for MDS relevant medication than those without 5q-deletion, though the level of significance is only 8%. Medication costs are illustrated in more detail in Fig. 2 , where medication costs are presented for both groups by indication category. In both groups, erythropoietin and iron chelation therapy are cost-driving factors within the medication cost category. The cost for iron chelation therapy in patients with 5q-deletion exceeds the figures for patients without deletion. Hospital-based outpatient services care, the base case value was also varied by 10% to explore its influence on the results. The base case cost of transfusion was based on expert experience. In the latter case, very different cost estimates were given. Therefore, the highest value was included in the base case, and the lowest value was tested in a sensitivity analysis. As higher bound of the sensitivity analysis, the base case value was increased by 10%. A tornado diagram (Fig. 3) shows the influence of the described variables on the results. It is shown that assumptions on the base case values of inpatient and outpatient care do not have a big influence on the overall outcomes. As the range tested for the transfusion cost was quite large (€80-€161.45 for erythrocytes and €350-€681.24 for thrombocytes), the results vary accordingly. When varying all variables as described at the same time in a multivariate analysis, the result ranges from €12,238 to €15,800. Lastly, the assumption of excluding periods where no information was available was tested. When no incurred costs for these quarters are assumed, total annual treatment cost were lowered by €600 to €14,286 per year. Hence, this assumption in the base case had no significant influence.
Discussion
This is the first MDS-costing study for Germany. Although few international MDS-costing studies exist, these studies cannot be compared with respect to their outcomes as all of them have different designs [14, 15, 32, 33] .
Casadevall et al. collected information utilization throughout a French clinical randomized controlled trial comparing recombinant human erythropoietin (rHuEPO) plus recombinant human granulocyte-colony-stimulating factor (rHuG-CSF) with supportive care. Based on data of 60 patients included into the study, they estimated the annual direct cost per patient to be €26,723 and €8,746, respectively. The study cohort substantially differs from the patients included in this study. Within their study, patients with cardiac, pulmonary, neurological, digestive, or genitourinary diseases or those having been treated with rHuEPO or rHuG-CSF within the previous 2 months were not included. Costs of co-morbidities are therefore not reflected, and costs of rHuEPO + rHuG-CSF might also be under-or overestimated compared to our cost estimates.
Gupta and colleagues estimated the median annual cost of transfusions in the United States to be $4,048 and $13,210 for the time from diagnosis to AML and from diagnosis of AML to secondary AML or death, respectively. Although this study did not exclude patients with co-morbidities, co-morbidities were not separately assessed and do not contribute to the overall cost estimates. Furthermore, only transfusion-related costs were included. Hence, these cost estimates are most likely to lie below the estimates of our study.
Brechignac et al. presented their ongoing work on the quality of life and economic impact of RBC transfusions at the ASH annual meeting in 2004. At that time, data of 38 patients were analyzed and resulted in per patient cost estimate over 2 years of €11,118. This did not include chelation therapy, which we found is a major cost driver.
Nonetheless, Frytag and others presented a study on economic burden of transfusion dependency at the 2005 ASCO annual meeting. Based on data of 338 transfusiondependent MDS patients, they estimated annualized medical transfusion-related cost to be $58,457 with annualized costs in the outpatient setting being estimated at $9,270. These cost estimates exceed our approximation by far. However, they found that among 20 patients with deferoxamine use, who have been continuously followed up over 1 year, the estimated cost per year was $7,437. In order to compare our cost estimates with those found by Frytak and colleagues, more details on the techniques used for annualizing those cost would be necessary. Within this study, it could be shown that MDS with an average annual cost of €14,883 per patient or €13,455 per patient in an office-based setting is a very resource-intensive disease, presenting a high burden to sickness funds as well as other payers. One additional interesting outcome seems to be that not only transfusions or transfusion-related services contribute to these costs but also co-morbidities, complications, and other medication.
Furthermore, one finding not backed by previous studies in the past showed that it may be that the costs of medication of MDS patients with 5q-deletion are higher in patients with isolated 5q-deletion, with the main driver being iron chelation therapy.
It was attempted to explain the extensive cost for iron chelation therapy in patients with isolated 5q-deletion. Iron chelation therapy is provided as prophylaxis for hemosiderosis in poly-transfused patients. In addition, the intensity of the iron chelation therapy depends on the iron overload of the patient which again is driven by the number of received transfusions. The database did not provide serum ferritin values. Therefore, the number of transfusions was used as approximation. However, the number of transfusions in both groups does not differ and hence, did not explain the increased cost for iron chelation therapy in 5q-patients. However, the intensive iron chelation therapy among patients with isolated 5q-deletion might be explained by the improved overall health of that group that is observed by clinical experts. Patients with isolated 5q-deletion tend to have a favorable prognosis with a lower risk of acute AML [9, 10] . Patients with a bad prognosis, i.e., with a very low life expectancy, might not receive as much expensive iron chelation therapy as those with a longer life expectancy.
There are some limitations to the outcomes of the present study. One problem arises with the selection of treatment sites in Germany where the data were retrospectively collected. Most patients with isolated 5q-deletion are sampled from one university outpatients department in Duesseldorf. It was shown that the data collected from the registry resulted in much higher cost estimates than the data from outpatient offices. However, the registry is based in a university hospital where some services had to be coded with EBM points retrospectively and where different reimbursement policies are applied. Thus, the explanation might be found in different administrative settings and in differences in the remuneration scheme of the centers. This hypothesis needs to be proven but lies beyond the scope of this study. As the patients in question within this study all need highly specialized care, treatment sites in the ambulatory setting are quite limited in Germany. We therefore tried to minimize potential bias by a geographical distribution of the study centers. Reflection of the daily treatment practice in Germany should therefore be given.
Even though this study excluded patients participating in ongoing lenalidomide trials to avoid not relevant trialdriven protocol related costs, patients sampled from the University of Duesseldorf might have been in trials of other compounds within or before the timeframe of the data collection. As clinical trial participants are usually followed more closely, are receiving more medical examination, and are providing more detailed anamnesis than patients not participating in trials, the reported difference in comorbidities between patients treated at the registry and those treated in offices might be biased in this study.
This study is performed from a payer's perspective. Hence, the estimated costs underestimate the real burden of MDS to society and also to affected patients. Not all provided services are reimbursed and therefore not considered in this study, making it most likely that the actual 14 direct costs of MDS are likely to exceed the €14,883 recorded in this study. From a patient's perspective, substantial additional direct costs might be borne by them. Furthermore, the study includes an average of 17 transfusions patient per year, and patients were observed in this analysis. This is a good representation of the non-monetary burden affecting quality of life of the patient and potentially caregivers within the family.
Further research in this area could use the analyzed costs in cost-effectiveness analyses trying to reflect different treatment scenarios of patients with MDS. Based on the different cost domains presented here, potential cost offsets in one area could be used to alter the treatment algorithm. The aim of this approach could be to potentially add quality of life for the patients and analyze how this would translate into cost-benefit ratios.
